Skip Navigation
Skip to contents

Intest Res : Intestinal Research

IMPACT FACTOR

Previous issues

Page Path
HOME > Browse articles > Previous issues
16 Previous issues
Filter
Filter
Article category
Keywords
Authors
Funded articles
Volume 19(4); October 2021
Prev issue Next issue
Editorial
IBD
Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
You Sun Kim
Intest Res 2021;19(4):357-359.   Published online October 26, 2021
DOI: https://doi.org/10.5217/ir.2021.00120
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Tissue quantitative RT–PCR test for diagnostic significance of cytomegalovirus infection in patients with inflammatory bowel disease and treatment response: Cytomegalovirus infection in patients with inflammatory bowel disease
    Burcu Ozdemir, Ali Atay, Meral Akdogan Kayhan, Yasemin Ozderin Ozin, Dilara Turan Gokce, Adalet Altunsoy, Rahmet Guner
    Medicine.2023; 102(31): e34463.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease
    Jun Lee
    The Korean Journal of Gastroenterology.2022; 80(2): 60.     CrossRef
  • 3,619 View
  • 126 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Reviews
Microbiota
Gut microbiome and checkpoint inhibitor colitis
Kanika Sehgal, Sahil Khanna
Intest Res 2021;19(4):360-364.   Published online December 1, 2020
DOI: https://doi.org/10.5217/ir.2020.00116
AbstractAbstract PDFPubReaderePub
Immune checkpoint inhibitor therapies such as ipilimumab, are increasingly being used as a treatment option for a variety of cancers, including metastatic melanoma and have demonstrated effectively a prolonged survival. These agents have an immunological mode of action that predisposes patients to a number of immune-related adverse events, colitis being one of the most commonly encountered complications. The pathogenesis for the development of colitis is unclear, and there is a growing consensus that the ecosystem of the gastrointestinal microbiota plays a significant role. Based on this suspected connection, studies are being carried out to explore the changes in the microbiota in patients on these medications who develop colitis. Conceivably, the modulation of the gut microbiota could offer a therapeutic benefit. Fecal microbiota transplantation is one therapeutic option that is currently being investigated, though there are still more data needed to evaluate its efficacy. In this review, we recapitulate the mechanisms of action of immune checkpoint inhibitors, their adverse events, with a focus on colitis and the role gut microbiota are suspected to play, and finally discuss the microbiota modulation therapies being investigated.

Citations

Citations to this article as recorded by  
  • Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
    Despoina Chrysostomou, Lauren A. Roberts, Julian R. Marchesi, James M. Kinross
    Gastroenterology.2023; 164(2): 198.     CrossRef
  • Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
    Seung Yong Shin, Young Kim, Won-Seok Kim, Jung Min Moon, Kang-Moon Lee, Sung-Ae Jung, Hyesook Park, Eun Young Huh, Byung Chang Kim, Soo Chan Lee, Chang Hwan Choi
    Intestinal Research.2023; 21(1): 148.     CrossRef
  • Obesity Measured via Body Mass Index May Be Associated with Increased Incidence but Not Worse Outcomes of Immune-Mediated Diarrhea and Colitis
    Miho Kono, Malek Shatila, Guofan Xu, Yang Lu, Antony Mathew, Wasay Mohajir, Krishnavathana Varatharajalu, Wei Qiao, Anusha S. Thomas, Yinghong Wang
    Cancers.2023; 15(8): 2329.     CrossRef
  • Gut microbiome homeostasis and the future of probiotics in cancer immunotherapy
    Ankita Singh, Sharon Grace Alexander, Sunil Martin
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Gut Microbiome and Colorectal Cancer
    Tae-Geun Gweon
    The Korean Journal of Gastroenterology.2023; 82(2): 56.     CrossRef
  • Impact ofHelicobacter pyloriinfection status on outcomes among patients with advanced gastric cancer treated with immune checkpoint inhibitors
    Patrick T Magahis, Steven B Maron, Darren Cowzer, Stephanie King, Mark Schattner, Yelena Janjigian, David Faleck, Monika Laszkowska
    Journal for ImmunoTherapy of Cancer.2023; 11(10): e007699.     CrossRef
  • Comments on Efficacy of a Synbiotic Containing Lactobacillus paracasei DKGF1 and Opuntia humifusa in Elderly Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
    Kwang Woo Kim
    Gut and Liver.2023; 17(6): 954.     CrossRef
  • MTA1 aggravates experimental colitis in mice by promoting transcription factor HIF1A and up-regulating AQP4 expression
    Ping Li, Dong-Ping Shi, Tao Jin, Dong Tang, Wei Wang, Liu-Hua Wang
    Cell Death Discovery.2022;[Epub]     CrossRef
  • Crosstalk between mucosal microbiota, host gene expression, and sociomedical factors in the progression of colorectal cancer
    Namjoo Kim, Jeong-An Gim, Beom Jae Lee, Byung il Choi, Hee Sook Yoon, Seung Han Kim, Moon Kyung Joo, Jong-Jae Park, Chungyeul Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Exploration of Potential Gut Microbiota-Derived Biomarkers to Predict the Success of Fecal Microbiota Transplantation in Ulcerative Colitis: A Prospective Cohort in Korea
    Gi-Ung Kang, Sowon Park, Yeongyun Jung, Jai J. Jee, Min-Sueng Kim, Seungjun Lee, Dong-Woo Lee, Jae-Ho Shin, Hong Koh
    Gut and Liver.2022; 16(5): 775.     CrossRef
  • Physical Activity as the Best Supportive Care in Cancer: The Clinician’s and the Researcher’s Perspectives
    Cécile Torregrosa, Frédéric Chorin, Eva Ester Molina Beltran, Cindy Neuzillet, Victoire Cardot-Ruffino
    Cancers.2022; 14(21): 5402.     CrossRef
  • Microbial Modulation in Inflammatory Bowel Diseases
    Jongwook Yu, Jae Hee Cheon
    Immune Network.2022;[Epub]     CrossRef
  • Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management
    Liansha Tang, Jialing Wang, Nan Lin, Yuwen Zhou, Wenbo He, Jiyan Liu, Xuelei Ma
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • 5,953 View
  • 295 Download
  • 13 Web of Science
  • 13 Crossref
Close layer
IBD
Crohn’s disease at radiological imaging: focus on techniques and intestinal tract
Giuseppe Cicero, Silvio Mazziotti
Intest Res 2021;19(4):365-378.   Published online November 25, 2020
DOI: https://doi.org/10.5217/ir.2020.00097
AbstractAbstract PDFPubReaderePub
Over recent years, inflammatory bowel diseases have become an issue of increased attention in daily clinical practice, due to both a rising incidence and improved imaging capability in detection. In particular, the diagnosis of Crohn’s disease is based on clinical picture, laboratory tests and colonoscopy with biopsy. However, colonoscopic evaluation is limited to the mucosal layer. Thus, imaging modalities play a pivotal role in enriching the clinical picture, delivering information on intestinal and extraintestinal involvement. All the imaging modalities can be employed in evaluation of Crohn’s disease patients, each of them with specific strengths as well as limitations. In this wide selection, the choice of a proper diagnostic framework can be challenging for the clinician. Therefore, the aim of this work is to offer an overview of the different imaging techniques, with brief technical details and diagnostic potential related to each intestinal tract.

Citations

Citations to this article as recorded by  
  • Comparison of an Endoscopic Scoring System and the Simplified Magnetic Resonance Index of Activity in Patients with Small Bowel Crohn’s Disease
    Ji Eun Na, Hon Soul Kim, Sung Noh Hong, Kyoung Doo Song, Ji Eun Kim, Eun Ran Kim, Young-Ho Kim, Dong Kyung Chang
    Gut and Liver.2024; 18(1): 97.     CrossRef
  • Duodenal Crohn’s disease: Case report and systematic review
    Muniratu Amadu, Jonathan Soldera
    World Journal of Methodology.2024;[Epub]     CrossRef
  • Achieving high-quality magnetic resonance enterography is critical for assessing Crohn’s disease activity
    Kyoung Doo Song
    Intestinal Research.2024; 22(2): 117.     CrossRef
  • Diagnostic Procedures for Inflammatory Bowel Disease: Laboratory, Endoscopy, Pathology, Imaging, and Beyond
    Seung Min Hong, Dong Hoon Baek
    Diagnostics.2024; 14(13): 1384.     CrossRef
  • Clinical applications, safety profiles, and future developments of contrast agents in modern radiology: A comprehensive review
    Reabal Najjar
    iRADIOLOGY.2024; 2(5): 430.     CrossRef
  • Could ultrasound alone substitute MR imaging in evaluation of Crohn’s disease complications?
    Hany El-Assaly, Asmaa Abdel Baky Mohamed, Hesham Adel Abdel Fattah Mustafa
    Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub]     CrossRef
  • Colonic involvement in inflammatory bowel diseases: spotlight on the role of magnetic resonance enterography
    Giuseppe Cicero, Velio Ascenti, Laura Maria Chisari, Silvio Mazziotti
    Japanese Journal of Radiology.2023;[Epub]     CrossRef
  • Impact of Crohn’s Disease on the Survival of Patients with Small-Bowel Adenocarcinoma in Korea: A Bicenter Cohort Study
    Kyuwon Kim, Kookhwan Choi, Sung Wook Hwang, Jong Pil Im, Byong Duk Ye, Joo Sung Kim, Kyu Joo Park, Suk-Kyun Yang, Seong-Joon Koh, Sang Hyoung Park
    Gut and Liver.2023; 17(4): 581.     CrossRef
  • Distribution of small bowel involvement and its association with clinical outcomes in patients with Crohn’s disease
    Jin Park, Hae Young Kim, Yoon Jin Lee, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee
    Medicine.2023; 102(40): e35040.     CrossRef
  • Reclassification of Inflammatory Bowel Disease Type Unclassified by Small Bowel Capsule Endoscopy
    Ana-Maria Singeap, Catalin Sfarti, Irina Girleanu, Laura Huiban, Cristina Muzica, Sergiu Timofeiov, Carol Stanciu, Anca Trifan
    Medicina.2023; 59(12): 2064.     CrossRef
  • Small Bowel Capsule Endoscopy and Enteroscopy: A Shoulder-to-Shoulder Race
    Ana-Maria Singeap, Catalin Sfarti, Horia Minea, Stefan Chiriac, Tudor Cuciureanu, Robert Nastasa, Carol Stanciu, Anca Trifan
    Journal of Clinical Medicine.2023; 12(23): 7328.     CrossRef
  • Crohn's disease and clinical management today: How it does?
    Ronaldo Teixeira da Silva Júnior, Jonathan Santos Apolonio, Jessica Oliveira de Souza Nascimento, Bruna Teixeira da Costa, Luciano Hasimoto Malheiro, Marcel Silva Luz, Lorena Sousa de Carvalho, Cleiton da Silva Santos, Fabrício Freire de Melo
    World Journal of Methodology.2023; 13(5): 399.     CrossRef
  • Mimicking conditions of intestinal Crohn’s disease: magnetic resonance enterography findings
    Giuseppe Cicero, Alfredo Blandino, Tommaso D’Angelo, Christian Booz, Thomas J. Vogl, Giorgio Ascenti, Silvio Mazziotti
    Japanese Journal of Radiology.2022; 40(1): 19.     CrossRef
  • Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases
    Yong Eun Park, Hye Su Moon, Dongeun Yong, Hochan Seo, Jinho Yang, Tae-Seop Shin, Yoon-Keun Kim, Jin Ran Kim, Yoo Na Lee, Young-Ho Kim, Joo Sung Kim, Jae Hee Cheon
    Scientific Reports.2022;[Epub]     CrossRef
  • Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice
    Kyeong Ok Kim
    Clinical Endoscopy.2022; 55(4): 480.     CrossRef
  • Overview of the Large Bowel Assessment using Magnetic Resonance Imaging: Different Techniques for Current and Emerging Clinical Applications
    Giuseppe Cicero, Giorgio Ascenti, Alfredo Blandino, Christian Booz, Thomas J. Vogl, Renato Trimarchi, Tommaso D'Angelo, Silvio Mazziotti
    Current Medical Imaging Formerly Current Medical Imaging Reviews.2022; 18(10): 1031.     CrossRef
  • Unique coexistence of chronic midgut malrotation, mesenteric cyst, and pancreas divisum in a Crohn's disease patient: MR-enterography assessment
    Giuseppe Cicero, Silvio Mazziotti
    Radiology Case Reports.2022; 17(11): 4280.     CrossRef
  • Portal hypertensive enteropathy: multimodality assessment through computed tomography and magnetic resonance enterography
    Giuseppe Cicero, Francesco Marcello Aricò, Anna Viola, Velio Ascenti, Silvio Mazziotti
    Radiology Case Reports.2022; 17(12): 4804.     CrossRef
  • DWI ratios: New indexes for Crohn’s disease activity at magnetic resonance enterography?
    Giuseppe Cicero, Angela Alibrandi, Alfredo Blandino, Velio Ascenti, Walter Fries, Anna Viola, Silvio Mazziotti
    La radiologia medica.2022;[Epub]     CrossRef
  • Elective surgery outcomes in inflammatory bowel disease: interpretation at magnetic resonance enterography
    Giuseppe Cicero, Giorgio Ascenti, Alfredo Blandino, Renato Trimarchi, Christian Booz, Thomas J. Vogl, Tommaso D’Angelo, Silvio Mazziotti
    Japanese Journal of Radiology.2021; 39(7): 633.     CrossRef
  • Magnetic resonance enterography in Crohn’s disease patients: current state of the art and future perspectives
    Hila Bufman, Rami Eliakim, Noam Tau, Michal Marianne Amitai
    Expert Review of Medical Devices.2021; 18(7): 657.     CrossRef
  • 11,210 View
  • 568 Download
  • 16 Web of Science
  • 21 Crossref
Close layer
Infection
An overview of the gut side of the SARS-CoV-2 infection
Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, Luana Zampieron Paza, Lara Luisa Valerio de Mello Braga, Fernanda da Silva Platner, Maria Fernanda de Paula Werner, Elizabeth Soares Fernandes, Daniele Maria-Ferreira
Intest Res 2021;19(4):379-385.   Published online November 6, 2020
DOI: https://doi.org/10.5217/ir.2020.00087
AbstractAbstract PDFPubReaderePub
In late 2019, an outbreak of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initiated in Wuhan, Hubei province, China. The major clinical symptoms described for coronavirus disease (COVID-19) include respiratory distress and pneumonia in severe cases, and some patients may experience gastrointestinal impairments. In accordance, viral RNA or live infectious virus have been detected in feces of patients with COVID-19. Binding of SARS-CoV-2 to the angiotensin‐converting enzyme 2 (ACE2) is a vital pathway for the virus entry into human cells, including those of the respiratory mucosa, esophageal epithelium as well as the absorptive enterocytes from ileum and colon. The interaction between SARS-CoV-2 and ACE2 receptor may decrease the receptor expression and disrupt the function of B0AT1 transporter influencing the diarrhea observed in COVID-19 patients. In this context, a fecal-oral transmission route has been considered and points out a role for the digestive tract in disease transmission and severity. Here, in order to further understand the impact of COVID-19 in human physiology, the cellular and molecular mechanisms of SARS-CoV-2 infection and disease severity are discussed in the context of gastrointestinal disturbances.

Citations

Citations to this article as recorded by  
  • COVID‐19 in a common woolly monkey (Lagothrix lagothricha): First evidence of fatal outcome in a nonhuman primate after natural SARS‐CoV‐2 infection
    Eduardo A. Diaz, Carolina Sáenz, Francisco Cabrera, Javier Rodríguez, Mateo Carvajal, Verónica Barragán
    American Journal of Primatology.2024;[Epub]     CrossRef
  • The COVID‐19 pandemic as a modifier of DGBI symptom severity: A systematic review and meta‐analysis
    Dmitrii Kulin, Ayesha Shah, Thomas Fairlie, Reuben K. Wong, Xiucai Fang, Uday C. Ghoshal, Purna C. Kashyap, Agata Mulak, Yeong Yeh Lee, Nicholas J. Talley, Natasha Koloski, Michael P. Jones, Gerald J. Holtmann
    Neurogastroenterology & Motility.2024;[Epub]     CrossRef
  • Disorders of gut-brain interaction in post-acute COVID-19 syndrome
    Rithvik Golla, Sudheer Kumar Vuyyuru, Bhaskar Kante, Saurabh Kedia, Vineet Ahuja
    Postgraduate Medical Journal.2023; 99(1174): 834.     CrossRef
  • Long-term Gastrointestinal Sequelae Following COVID-19: A Prospective Follow-up Cohort Study
    Rithvik Golla, Sudheer Vuyyuru, Bhaskar Kante, Peeyush Kumar, David Mathew Thomas, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Clinical Gastroenterology and Hepatology.2023; 21(3): 789.     CrossRef
  • Impacts of COVID-19 in Breast Cancer: From Molecular Mechanism to the Treatment Approach
    Maria Carolina Stipp, Claudia Rita Corso, Alexandra Acco
    Current Pharmaceutical Biotechnology.2023; 24(2): 238.     CrossRef
  • Vaccination strategies for Korean patients with inflammatory bowel disease
    Yoo Jin Lee, Eun Soo Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 920.     CrossRef
  • Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
    Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
    Intestinal Research.2022; 20(4): 431.     CrossRef
  • Diarrhea Is a Hallmark of Inflammation in Pediatric COVID-19
    Marco Poeta, Francesco Nunziata, Margherita Del Bene, Francesca Morlino, Alessia Salatto, Sara Maria Scarano, Valentina Cioffi, Michele Amitrano, Eugenia Bruzzese, Alfredo Guarino, Andrea Lo Vecchio
    Viruses.2022; 14(12): 2723.     CrossRef
  • Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy
    Lorenzo Iovino, Laurel A Thur, Sacha Gnjatic, Aude Chapuis, Filippo Milano, Joshua A Hill
    Journal for ImmunoTherapy of Cancer.2021; 9(5): e002392.     CrossRef
  • KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement
    Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
    The Korean Journal of Gastroenterology.2021; 78(2): 105.     CrossRef
  • Host Response to SARS-CoV2 and Emerging Variants in Pre-Existing Liver and Gastrointestinal Diseases
    Baibaswata Nayak, Geetanjali Lal, Sonu Kumar, Chandan J. Das, Anoop Saraya, Shalimar
    Frontiers in Cellular and Infection Microbiology.2021;[Epub]     CrossRef
  • Diosmectite inhibits the interaction between SARS-CoV-2 and human enterocytes by trapping viral particles, thereby preventing NF-kappaB activation and CXCL10 secretion
    Marco Poeta, Valentina Cioffi, Vittoria Buccigrossi, Merlin Nanayakkara, Melissa Baggieri, Roberto Peltrini, Angela Amoresano, Fabio Magurano, Alfredo Guarino
    Scientific Reports.2021;[Epub]     CrossRef
  • Molecular Mechanisms of Possible Action of Phenolic Compounds in COVID-19 Protection and Prevention
    Nikola Gligorijevic, Mirjana Radomirovic, Olgica Nedic, Marija Stojadinovic, Urmila Khulal, Dragana Stanic-Vucinic, Tanja Cirkovic Velickovic
    International Journal of Molecular Sciences.2021; 22(22): 12385.     CrossRef
  • Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study
    Jin Wook Lee, Eun Mi Song, Sung-Ae Jung, Sung Hoon Jung, Kwang Woo Kim, Seong-Joon Koh, Hyun Jung Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Journal of Korean Medical Science.2021;[Epub]     CrossRef
  • 7,451 View
  • 354 Download
  • 18 Web of Science
  • 14 Crossref
Close layer
Original Articles
Inflammatory Bowel Diseases
Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, Yasuo Suzuki, Yoshifumi Ohnishi, Noriyuki Fujii, Nobuko Matsushima, Richuan Zheng, Colleen W. Marano
Intest Res 2021;19(4):386-397.   Published online December 1, 2020
DOI: https://doi.org/10.5217/ir.2020.00080
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative colitis (UC).
Methods
This sub-analysis was conducted on data from East-Asian patients included in the UNIFI program (NCT02407236). UNIFI consisted of two double-blind, placebo-controlled trials: an 8-week induction study and a 44-week randomized withdrawal maintenance study.
Results
Of 133 East-Asian patients (Japanese: 107, Korean: 26) who underwent randomization, 131 completed induction study and 111 entered maintenance study. In the maintenance study, 78 patients were randomized. Patients who received UST 130 mg and UST 6 mg/kg showed numerically higher clinical remission at week 8 in the induction study (5/44 [11.4%] and 5/45 [11.1%], respectively) compared with those who received placebo (0/44, 0%). The proportion of patients achieved clinical remission at week 44 was numerically higher in the UST 90 mg q12w group (10/21, 47.6%), but similar in the UST 90 mg q8w group (5/26, 19.2%) compared to placebo (7/31, 22.6%). Serious adverse events were reported in 1 patient in UST 130 mg group, but no patient in UST 6 mg/kg group through week 8 in the induction study, and 1 patient in UST 90 mg q12w group and 5 patients in the UST 90 mg q8w group in the maintenance study. No deaths were reported in East-Asian patients throughout the study.
Conclusions
UST induction and maintenance treatments were effective in East-Asian patients with moderate to severe UC; the efficacy and safety profiles were consistent with the overall population.

Citations

Citations to this article as recorded by  
  • Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease
    Abhinav Vasudevan, Vivek Tharayil, Laura H Raffals, David H Bruining, Michelle Becker, Mohammad Hassan Murad, Edward V Loftus
    Inflammatory Bowel Diseases.2024; 30(4): 660.     CrossRef
  • Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis
    Hiromu Morikubo, Ryuta Tojima, Tsubasa Maeda, Katsuyoshi Matsuoka, Minoru Matsuura, Jun Miyoshi, Satoshi Tamura, Tadakazu Hisamatsu
    Scientific Reports.2024;[Epub]     CrossRef
  • Hepatic Steatosis but Not Fibrosis Is Independently Associated with Poor Outcomes in Patients with Inflammatory Bowel Disease
    Hye Kyung Hyun, Hye Won Lee, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
    Gut and Liver.2024; 18(2): 294.     CrossRef
  • Machine Learning for Predicting Biologic Agent Efficacy in Ulcerative Colitis: An Analysis for Generalizability and Combination with Computational Models
    Philippe Pinton
    Diagnostics.2024; 14(13): 1324.     CrossRef
  • One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn’s Disease: The K-STAR Study
    Chang Kyun Lee, Won Moon, Jaeyoung Chun, Eun Soo Kim, Hyung Wook Kim, Hyuk Yoon, Hyun Soo Kim, Yoo Jin Lee, Chang Hwan Choi, Yunho Jung, Sung Chul Park, Geun Am Song, Jong Hun Lee, Eun Suk Jung, Youngdoe Kim, Su Young Jung, Jong Min Choi, Byong Duk Ye
    Inflammatory Bowel Diseases.2024;[Epub]     CrossRef
  • Risks of colorectal cancer and biliary cancer according to accompanied primary sclerosing cholangitis in Korean patients with ulcerative colitis: a nationwide population-based study
    Eun Hye Oh, Ye-Jee Kim, Minju Kim, Seung Ha Park, Tae Oh Kim, Sang Hyoung Park
    Intestinal Research.2023; 21(2): 252.     CrossRef
  • A critical review of ustekinumab for the treatment of active ulcerative colitis in adults
    Sophie Vieujean, Edouard Louis, Silvio Danese, Laurent Peyrin-Biroulet
    Expert Review of Gastroenterology & Hepatology.2023; 17(5): 413.     CrossRef
  • Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
    Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
    Intestinal Research.2023; 21(2): 174.     CrossRef
  • Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
    Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim
    Intestinal Research.2023; 21(2): 244.     CrossRef
  • The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
    Myeong Geun Choi, Byong Duk Ye, Suk-Kyun Yang, Tae Sun Shim, Kyung-Wook Jo, Sang Hyoung Park
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Japanese pediatric patient with moderately active ulcerative colitis successfully treated with ustekinumab
    Toshihiko Kakiuchi, Masato Yoshiura
    Medicine.2022; 101(7): e28873.     CrossRef
  • Personalized medicine in inflammatory bowel disease: Perspectives on Asia
    Su Hyun Park, Sang Hyoung Park
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
  • Antitumor necrosis factor treatment in patients with inflammatory bowel disease does not promote psoriasis development: A meta-analysis
    Yu Kyung Jun, Joo Young Park, Seong-Joon Koh, Hyunsun Park, Hyoun Woo Kang, Jong Pil Im, Joo Sung Kim
    Medicine.2022; 101(27): e29872.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
    Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
    Gut and Liver.2022; 16(5): 764.     CrossRef
  • Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
    Soo-Young Na, You Sun Kim
    The Korean Journal of Internal Medicine.2022; 37(5): 906.     CrossRef
  • Natural history of inflammatory bowel disease: a comparison between the East and the West
    Eun Mi Song, Suk-Kyun Yang
    Intestinal Research.2022; 20(4): 418.     CrossRef
  • Current status of inflammatory bowel diseases in Korea
    Suk-Kyun Yang
    Journal of the Korean Medical Association.2021; 64(9): 572.     CrossRef
  • 6,724 View
  • 426 Download
  • 19 Web of Science
  • 18 Crossref
Close layer
Inflammatory Bowel Diseases
Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
Intest Res 2021;19(4):398-407.   Published online November 20, 2020
DOI: https://doi.org/10.5217/ir.2020.00107
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Information on pediatric inflammatory bowel disease (PIBD) and very early onset IBD (VEOIBD) are sparse in India, where IBD is emerging. We aimed to evaluate characteristics of VEOIBD and later onset PIBD (LO-PIBD) in India.
Methods
We performed retrospective analysis of a large, prospectively maintained IBD registry. PIBD was divided in to VEOIBD ( < 6 years) and LO-PIBD (6–17 years). Demographic data, disease characteristics and treatment were compared between the PIBD groups and with other Asian/Western studies as well as the adult patients of the registry.
Results
Of 3,752 IBD patients, 292 (7.8%) had PIBD (0–17 years) (175 Crohn’s disease [CD], 113 ulcerative colitis [UC], 4 IBD-undifferentiated; 22 VEOIBD [7.5%], and 270 LO-PIBD [92.5%]). VEOIBD patients had more severe disease compared to LO-PIBD in both UC (P= 0.003) and CD (P< 0.001). Familial IBD was more common in VEOIBD (13.6%) compared to LO-PIBD (9.2%). Ileal disease (L1) was an independent risk factor for diagnostic delay in pediatric CD. Diagnostic delay ( > 6 months) was significantly lower in VEOIBD (40.9%) than in LO-PIBD (78.8%) (P< 0.001). Compared to other Asian and Western studies, extensive UC (72.5%) and complicated CD (stricturing/penetrating: 42.7%) were relatively more common. Perianal CD was relatively less frequent (7.4%). PIBD had a significantly higher number of complicated and ileal CD and extensive UC comparison to adult cohort of the registry.
Conclusions
VEOIBD has more aggressive phenotype than LO-PIBD. Disease appears distinct from other Asian and Western studies and adult onset disease, with more complicated CD and extensive UC.

Citations

Citations to this article as recorded by  
  • Spectrum and trend of pediatric inflammatory bowel disease: A two-decade experience from northern India
    Neelam Mohan, Shivani Deswal, Anubhuti Bhardwaj
    Indian Journal of Gastroenterology.2024; 43(1): 208.     CrossRef
  • Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
    Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
    Journal of Gastroenterology and Hepatology.2023; 38(4): 523.     CrossRef
  • Very-early-onset inflammatory bowel disease versus late-onset inflammatory bowel disease in relation to clinical phenotype: A cross-sectional study
    Hala H. Mansour, Saeed S. Seddek, Manal E. Abd E. L. Meguid, Ayman E. Eskander, Sara T. Galal
    Indian Journal of Gastroenterology.2023; 42(2): 185.     CrossRef
  • Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review
    M. Ellen Kuenzig, Stephen G. Fung, Luba Marderfeld, Joyce W.Y. Mak, Gilaad G. Kaplan, Siew C. Ng, David C. Wilson, Fiona Cameron, Paul Henderson, Paulo G. Kotze, Jasmine Bhatti, Vixey Fang, Samantha Gerber, Evelyne Guay, Supun Kotteduwa Jayawarden, Leo Ka
    Gastroenterology.2022; 162(4): 1147.     CrossRef
  • Epidemiological characteristics of Asian children with inflammatory bowel disease at diagnosis: Insights from an Asian-Pacific multi-centre registry network
    James Guoxian Huang, Yoko Kin Yoke Wong, Kee Seang Chew, Pornthep Tanpowpong, Karen Sophia Calixto Mercado, Almida Reodica, Shaman Rajindrajith, Kai-Chi Chang, Yen-Hsuan Ni, Suporn Treepongkaruna, Way-Seah Lee, Marion Margaret Aw
    World Journal of Gastroenterology.2022; 28(17): 1830.     CrossRef
  • Personalized medicine in inflammatory bowel disease: Perspectives on Asia
    Su Hyun Park, Sang Hyoung Park
    Journal of Gastroenterology and Hepatology.2022; 37(8): 1434.     CrossRef
  • Inflammatory bowel disease in Korea: epidemiology and pathophysiology
    Jung Won Lee, Chang Soo Eun
    The Korean Journal of Internal Medicine.2022; 37(5): 885.     CrossRef
  • Racial and Ethnic Variation in Presentation, Diagnosis, Treatment, and Outcome of Pediatric Crohn Disease: A Single Center Study
    Savini Lanka Britto, Justin Qian, Faith Dorsey Ihekweazu, Richard Kellermayer
    Journal of Pediatric Gastroenterology & Nutrition.2022; 75(3): 313.     CrossRef
  • Phenotypic Pattern of Early Versus Later-Onset Pediatric Inflammatory Bowel Disease in a Eurasian Country
    Bilge S. Akkelle, Deniz Ertem, Burcu Volkan, Engin Tutar
    Journal of Pediatric Gastroenterology & Nutrition.2022; 75(4): e61.     CrossRef
  • Clinical Features and Long-Term Outcomes of Paediatric-Onset Inflammatory Bowel Disease in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
    Sang Hyoung Park, Jong Pil Im, Hyunju Park, Seung Kyu Jeong, Ji Hyun Lee, Kyoung Hoon Rhee, Young-Ho Kim, Sung Noh Hong, Kyung Ho Kim, Seung In Seo, Jae Myung Cha, Sun Yong Park, Joo Sung Kim, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
    Journal of Crohn's and Colitis.2021;[Epub]     CrossRef
  • Predictors of Positive Video Capsule Endoscopy Findings for Chronic Unexplained Abdominal Pain: Single-Center Retrospective Study and Meta-Analysis
    Wonshik Kim, Beomjae Lee, Ahyoung Yoo, Seunghan Kim, Moonkyung Joo, Jong-Jae Park
    Diagnostics.2021; 11(11): 2123.     CrossRef
  • 9,028 View
  • 219 Download
  • 13 Web of Science
  • 11 Crossref
Close layer
Inflammatory Bowel Diseases
Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, Takashi Hagiwara, Takeshi Kawaberi, Haruhiko Ogata, Toshiyuki Matsui, Mamoru Watanabe, Toshifumi Hibi
Intest Res 2021;19(4):408-418.   Published online November 20, 2020
DOI: https://doi.org/10.5217/ir.2020.00025
AbstractAbstract PDFPubReaderePub
Background/Aims
Crohn’s disease is a chronic disorder; therefore, it is essential to investigate long-term safety and efficacy of treatments. This study assessed the safety and effectiveness of adalimumab for up to 3 years in Japanese patients with Crohn’s disease in real-world settings.
Methods
This was a multicenter, single-cohort, observational study of patients with Crohn’s disease. Safety assessments included incidence of adverse drug reactions. Effectiveness assessments included clinical remission, mucosal healing, and Work Productivity and Activity Impairment (WPAI).
Results
The safety and effectiveness analysis populations comprised 389 and 310 patients, respectively. Mean (standard deviation) exposure to adalimumab in the safety analysis population was 793.4 (402.8) days, with a 58.1% retention rate. A total of 105 patients (27.0%) and 43 patients (11.1%) experienced adverse drug reactions and serious adverse drug reactions, respectively, with no patient reporting tuberculosis or hepatitis B. Infections and serious infections were reported in 37 patients (9.5%) and 17 patients (4.4%), respectively. Malignancy was reported as an adverse drug reaction in 2 patients (0.5%). Remission rate increased from 37.8% (98/259) at baseline to 73.9% (167/226) at week 4 and remained > 70% over 3 years. Proportion of patients without mucosal ulcerations increased from 2.7% (2/73) at baseline to 42.3% (11/26) between years > 2 to ≤ 3. WPAI improvement started at 4 weeks, with the overall work impairment score improving from 42.7 (n = 102) at baseline to 26.9 (n = 84) at 4 weeks.
Conclusions
Results from this study confirm the long-term safety and effectiveness of adalimumab treatment in Japanese patients with Crohn’s disease in the real-world setting.

Citations

Citations to this article as recorded by  
  • Effect of Perianal Fistula on the Quality of Life and Work Productivity of Patients with Crohn's Disease: Report of a Questionnaire Survey
    Naoto Saigusa, Takeshi Inaba
    Nippon Daicho Komonbyo Gakkai Zasshi.2024; 77(2): 89.     CrossRef
  • Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
    Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
    The Korean Journal of Internal Medicine.2023; 38(5): 661.     CrossRef
  • Clinical features of enteric and colo-duodenal fistula in patients with Crohn’s disease
    Jun Su Lee, Sang-Bum Kang, Kwangbeom Park, Yong Sik Yoon, Chang Sik Yu, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Jong Lyul Lee, Sang Hyoung Park
    Intestinal Research.2023; 21(3): 406.     CrossRef
  • TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors
    Julie J. Hong, Edward K. Hadeler, Megan L. Mosca, Nicholas D. Brownstone, Tina Bhutani, Wilson J. Liao
    Journal of Psoriasis and Psoriatic Arthritis.2022; 7(2): 79.     CrossRef
  • Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
    Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
    Gut and Liver.2022; 16(1): 138.     CrossRef
  • Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician
    Adam Saleh, Usman Ansari, Shaadi Abughazaleh, Kerri Glassner, Bincy P Abraham
    Biologics: Targets and Therapy.2022; Volume 16: 67.     CrossRef
  • Prevention of postoperative recurrence in Crohn’s disease: the never-ending story
    Jung-Bin Park, Sang Hyoung Park
    Intestinal Research.2022; 20(3): 279.     CrossRef
  • Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
    Jihye Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2022; 37(5): 895.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
    Juntao Yin, Yang Li, Yangyang Chen, Chaoyang Wang, Xiaoyong Song
    European Journal of Medical Research.2022;[Epub]     CrossRef
  • Natural history of inflammatory bowel disease: a comparison between the East and the West
    Eun Mi Song, Suk-Kyun Yang
    Intestinal Research.2022; 20(4): 418.     CrossRef
  • Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
    Jihye Park, Jae Hee Cheon
    Gut and Liver.2021; 15(5): 641.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 6,111 View
  • 327 Download
  • 17 Web of Science
  • 13 Crossref
Close layer
Inflammatory Bowel Diseases
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, Mariko Kobayashi, Toshifumi Hibi
Intest Res 2021;19(4):419-429.   Published online November 10, 2020
DOI: https://doi.org/10.5217/ir.2020.00033
AbstractAbstract PDFPubReaderePub
Background/Aims
Adalimumab has been shown to induce and maintain clinical remission in patients with moderate to severe ulcerative colitis (UC). However, no large-scale population-based studies have been performed in Japan. This study was conducted to evaluate the safety and effectiveness of adalimumab in clinical practice in Japanese patients with UC.
Methods
In this 52-week, prospective, multicenter, single-cohort, noninterventional, observational, postmarketing surveillance study, patients with moderate to severe UC received an initial subcutaneous injection of adalimumab 160 mg, followed by 80 mg at 2 weeks, and then 40 mg every other week. Safety assessments were the incidence of adverse drug reactions (ADRs) and serious ADRs. Effectiveness assessments were clinical remission, corticosteroid-free remission, mucosal healing, and change in C-reactive protein (CRP) levels from baseline.
Results
Of 1,593 registered patients, 1,523 (male, 57.6%; mean age, 41.8 years) and 1,241 patients were included in the safety and effectiveness populations, respectively. ADRs were reported in 18.1% and serious ADRs in 4.9% of patients. Clinical remission was achieved in 49.7% of patients at week 4, increasing to 74.4% at week 52. Corticosteroid-free remission rates increased over time, from 10.4% at week 4 to 53.1% at week 52. More than 60% of patients demonstrated mucosal healing at weeks 24 and 52. Mean CRP levels (mg/dL) decreased from 1.2 at baseline to 0.6 at week 4 and 0.3 at week 52.
Conclusions
This large real-world study confirmed the safety and effectiveness of adalimumab in patients with UC in Japan. No new safety concerns were identified.

Citations

Citations to this article as recorded by  
  • Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
    Peter M. Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire
    Journal of Managed Care & Specialty Pharmacy.2024; 30(9): 1026.     CrossRef
  • Real‐world experience of adalimumab therapy for patients with ulcerative colitis: A single tertiary medical center experience in Central Taiwan
    Hsu‐Heng Yen, Yu‐Chun Hsu, Chu‐Hsuan Kuo, Tsui‐Chun Hsu, Yang‐Yuan Chen
    Advances in Digestive Medicine.2023; 10(1): 28.     CrossRef
  • Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
    Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
    Intestinal Research.2023; 21(2): 174.     CrossRef
  • Safety of Adalimumab: An Analysis of the FDA Adverse Event Reporting System (FAERS) Database
    Buthainah Ghanem
    Jordan Journal of Pharmaceutical Sciences.2023; 16(3): 517.     CrossRef
  • Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?
    Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
    Gut and Liver.2022; 16(1): 138.     CrossRef
  • Adalimumab Efficacy for Management of Inflammatory Bowel Disease in Southwest Region of Iran
    Pezhman Alavinejad, Sana Delavari, Abazar Parsi, Ali Akbar Shayesteh
    Modern Care Journal.2022;[Epub]     CrossRef
  • Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
    Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Ki
    Intestinal Research.2022; 20(3): 350.     CrossRef
  • Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
    Jihye Park, Jae Hee Cheon
    The Korean Journal of Internal Medicine.2022; 37(5): 895.     CrossRef
  • Viral Hepatitis in Patients with Inflammatory Bowel Disease
    Seung Hwan Shin, Sang Hyoung Park
    The Korean Journal of Gastroenterology.2022; 80(2): 51.     CrossRef
  • Do We Have an Opportunity to Avoid Opportunistic Infections in Asian Patients with Inflammatory Bowel Disease?
    Suhyun Park, Sang Hyoung Park
    Gut and Liver.2022; 16(5): 663.     CrossRef
  • Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease
    Byung Chul Jin, Hee Jin Moon, Sang Wook Kim
    The Korean Journal of Gastroenterology.2022; 80(2): 72.     CrossRef
  • Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
    Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
    Gut and Liver.2022; 16(5): 764.     CrossRef
  • Circulating Profile of ECM-Related Proteins as Diagnostic Markers in Inflammatory Bowel Diseases
    Katarzyna Komosinska-Vassev, Aleksandra Kałużna, Agnieszka Jura-Półtorak, Alicja Derkacz, Krystyna Olczyk
    Journal of Clinical Medicine.2022; 11(19): 5618.     CrossRef
  • Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
    Jihye Park, Jae Hee Cheon
    Gut and Liver.2021; 15(5): 641.     CrossRef
  • 6,332 View
  • 344 Download
  • 13 Web of Science
  • 14 Crossref
Close layer
Inflammatory Bowel Diseases
Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy
Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, Kana Onishi, Takeshi Takasago, Masaki Wakai, Toshikatsu Naito, Kensuke Sasaki, Shigehiro Doi, Takao Masaki, Kazuaki Chayama
Intest Res 2021;19(4):430-437.   Published online November 9, 2020
DOI: https://doi.org/10.5217/ir.2020.00067
AbstractAbstract PDFPubReaderePub
Background/Aims
Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract. Some patients with this condition have been reported to present with immunoglobulin A nephropathy (IgAN), a renal complication that can cause end-stage renal failure, but the frequency of this comorbidity has not been described. Thus, the aim of this study was to investigate the frequency of IgAN in patients with IBD.
Methods
This study included 620 patients with IBD (338 with ulcerative colitis [UC] and 282 with Crohn’s disease [CD]) from the Hiroshima University Hospital outpatient department. IgAN cases were identified from medical interviews, blood examinations (serum immunoglobulin A), and urinalyses (occult blood, proteinuria). Definitive IgAN cases were diagnosed by renal biopsies, while those detected through the clinical course and test results, but not clinically recommended for renal biopsy, were defined as suspected IgAN.
Results
We analyzed 427 cases meeting the inclusion criteria (220 with UC and 207 with CD). The incidence of IgAN across all patients with IBD was 3.0%. The frequency of IgAN was significantly higher in patients with CD (11/207, 5.3%) than in those with UC (2/220, 0.9%) (P< 0.01). Moreover, a significant correlation was found between CD patients with ileostomy or colostomy and a diagnosis of IgAN.
Conclusions
Patients with IBD present a high incidence of IgAN, especially those with CD who have undergone ileostomy or colostomy.

Citations

Citations to this article as recorded by  
  • Safety of Biologics and Small Molecules for Inflammatory Bowel Diseases in Organ Transplant Recipients
    Ga Hee Kim, Minjun Kim, Kyuwon Kim, Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
    Yonsei Medical Journal.2024; 65(5): 276.     CrossRef
  • Indirect Markers of Intestinal Damage in IgA Nephropathy
    Jussi Pohjonen, Katri Kaukinen, Heini Huhtala, Ilkka Pörsti, Katri Lindfors, Jukka Mustonen, Satu Mäkelä
    Nephron.2024; 148(10): 693.     CrossRef
  • Insights into renal and urological complications of inflammatory bowel disease
    Anmol Singh, Tejasvini Khanna, Diksha Mahendru, Jasraj Kahlon, Vikash Kumar, Aalam Sohal, Juliana Yang
    World Journal of Nephrology.2024;[Epub]     CrossRef
  • Risk of all-cause and cause-specific mortality associated with immune-mediated inflammatory diseases in Korea
    Oh Chan Kwon, See Young Lee, Jaeyoung Chun, Kyungdo Han, Yuna Kim, Ryul Kim, Min-Chan Park, Jie-Hyun Kim, Young Hoon Youn, Hyojin Park
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Kidney Diseases Associated With Inflammatory Bowel Disease: Impact of Chronic Histologic Damage, Treatments, and Outcomes
    Federico Yandian, Fernando Caravaca-Fontán, Loren P. Herrera Hernandez, Maria José Soler, Sanjeev Sethi, Fernando C. Fervenza
    Kidney International Reports.2023;[Epub]     CrossRef
  • Active flare of IgA nephropathy during long-term therapy with anti-tumor necrosis factor-α antibody drugs for Crohn’s disease: three case reports and literature review
    Akihiro Shimizu, Nobuo Tsuboi, Kotaro Haruhara, Izumi Shirai, Kyohei Ogawa, Akane Miura, Kentaro Oshiro, Hiroyuki Ueda, Shinya Yokote, Masahiro Okabe, Takaya Sasaki, Masato Ikeda, Takashi Yokoo
    CEN Case Reports.2023; 13(4): 249.     CrossRef
  • Differentiation of T Helper 17 Cells May Mediate the Abnormal Humoral Immunity in IgA Nephropathy and Inflammatory Bowel Disease Based on Shared Genetic Effects
    Jianbo Qing, Changqun Li, Xueli Hu, Wenzhu Song, Hasna Tirichen, Hasnaa Yaigoub, Yafeng Li
    Frontiers in Immunology.2022;[Epub]     CrossRef
  • 5,957 View
  • 171 Download
  • 6 Web of Science
  • 7 Crossref
Close layer
Inflammatory Bowel Diseases
High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis
Saransh Jain, Divya Namdeo, Pabitra Sahu, Saurabh Kedia, Peush Sahni, Prasenjit Das, Raju Sharma, Vipin Gupta, Govind Makharia, Lalit Dar, Simon PL Travis, Vineet Ahuja
Intest Res 2021;19(4):438-447.   Published online November 6, 2020
DOI: https://doi.org/10.5217/ir.2020.00055
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
Predictors of short-term outcome of intravenous (IV) steroid therapy in acute severe ulcerative colitis (ASUC) have been well described, but the impact of cytomegalovirus (CMV) infection as a predictor of outcome remains debatable. We investigated the role of quantitative CMV polymerase chain reaction (PCR) as a predictor of short-term outcome in patients with ASUC.
Methods
Consecutive patients with ASUC satisfying Truelove and Witts criteria hospitalized at All India Institute of Medical Sciences (AIIMS) from May 2016 to July 2019 were included; all received IV steroid. The primary outcome measure was steroid-failure defined as the need for rescue therapy (with ciclosporin or infliximab) or colectomy during admission. AIIMS’ index (ulcerative colitis index of severity > 6 at day 1+fecal calprotectin > 1,000 μg/g at day 3), with quantitative CMV PCR on biopsy samples obtained at initial sigmoidoscopy were correlated with the primary outcome.
Results
Thirty of 76 patients (39%) failed IV corticosteroids and 12 (16%) underwent surgery. Patients with steroid failure had a significantly higher mucosal CMV DNA than responders (3,454 copies/mg [0–2,700,000] vs. 116 copies/mg [0–27,220]; P< 0.01). On multivariable analysis, mucosal CMV DNA load > 2,000 copies/mg (odds ratio [OR], 10.2; 95% confidence interval [CI], 2.6–39.7; P< 0.01) and AIIMS’ index (OR, 39.8; 95% CI, 4.4–364.4; P< 0.01) were independent predictors of steroid-failure and need for colectomy. The combination correctly predicted outcomes in 84% of patients with ASUC.
Conclusions
High mucosal CMV DNA ( > 2,000 copies/mg) independently predicts failure of IV corticosteroids and short-term risk of colectomy and it has an additional value to the established markers of disease severity in patients with ASUC.

Citations

Citations to this article as recorded by  
  • Systematic Review: Outcome Prediction in Acute Severe Ulcerative Colitis
    Julia Angkeow, Alissa Rothman, Lara Chaaban, Nicole Paul, Joanna Melia
    Gastro Hep Advances.2024; 3(2): 260.     CrossRef
  • Predictors of adverse outcomes of steroids in patients with severe ulcerative colitis (systematic review and meta-analyses)
    A. F. Mingazov, O. I. Sushkov, B. R. Kalanov, T. A. Baranova, S. I. Achkasov
    Koloproktologia.2024; 23(1): 172.     CrossRef
  • Predicting Outcome after Acute Severe Ulcerative Colitis: A Contemporary Review and Areas for Future Research
    Sudheer Kumar Vuyyuru, Olga Maria Nardone, Vipul Jairath
    Journal of Clinical Medicine.2024; 13(15): 4509.     CrossRef
  • Low prevalence of Clostridioides difficile infection in acute severe ulcerative colitis: A retrospective cohort study from northern India
    Sandeep Mundhra, David Thomas, Saransh Jain, Pabitra Sahu, Sudheer Vuyyuru, Peeyush Kumar, Bhaskar Kante, Rajesh Panwar, Peush Sahni, Rama Chaudhry, Prasenjit Das, Govind Makharia, Saurabh Kedia, Vineet Ahuja
    Indian Journal of Gastroenterology.2023; 42(3): 411.     CrossRef
  • The role of cytomegalovirus colitis on short- and long-term outcomes for patients with ulcerative colitis
    Mengmeng Zhang, Xiaoyin Bai, Huimin Zhang, Yan You, Hong Lv, Yue Li, Bei Tan, Ji Li, Hui Xu, Weiyang Zheng, Hong Yang, Jiaming Qian
    Scandinavian Journal of Gastroenterology.2022; 57(3): 282.     CrossRef
  • Cytomegalovirus in ulcerative colitis: an evidence-based approach to diagnosis and treatment
    Anuraag Jena, Shubhra Mishra, Anupam Kumar Singh, Aravind Sekar, Vishal Sharma
    Expert Review of Gastroenterology & Hepatology.2022; 16(2): 109.     CrossRef
  • Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis
    Pabitra Sahu, Saransh Jain, Saurabh Kedia, Sudheer K. Vuyyuru, Peush Sahni, Raju Sharma, Rajesh Panwar, Prasenjit Das, Vipin Gupta, Govind Makharia, Simon Travis, Vineet Ahuja
    Indian Journal of Gastroenterology.2022; 41(3): 273.     CrossRef
  • Cytomegalovirus Infection in Patients with Inflammatory Bowel Disease
    Jun Lee
    The Korean Journal of Gastroenterology.2022; 80(2): 60.     CrossRef
  • The Impact of Human Herpesviruses in Clinical Practice of Inflammatory Bowel Disease in the Era of COVID-19
    Shuhei Hosomi, Yu Nishida, Yasuhiro Fujiwara
    Microorganisms.2021; 9(9): 1870.     CrossRef
  • Does cytomegalovirus load predict the outcome of acute severe ulcerative colitis?
    You Sun Kim
    Intestinal Research.2021; 19(4): 357.     CrossRef
  • 5,787 View
  • 212 Download
  • 8 Web of Science
  • 10 Crossref
Close layer
Inflammatory Bowel Diseases
Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
Intest Res 2021;19(4):448-460.   Published online August 18, 2020
DOI: https://doi.org/10.5217/ir.2020.00026
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Background/Aims
A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy of a new vedolizumab subcutaneous (SC) formulation.
Methods
Eligible patients received open-label infusions of vedolizumab 300 mg intravenous (IV) at weeks 0 and 2 in the induction phase. Patients with clinical response by complete Mayo score at week 6 entered the double-blind maintenance phase and were randomized to vedolizumab 108 mg SC every 2 weeks, placebo, or vedolizumab 300 mg IV every 8 weeks. The primary endpoint was clinical remission (complete Mayo score ≤ 2 points; no individual subscore > 1 point) at week 52.
Results
Of 49 patients who entered the induction phase, 22 out of 49 patients (45%) had clinical response at week 6 and were randomized to vedolizumab 108 mg SC (n = 10), placebo (n = 10), or vedolizumab 300 mg IV (n = 2). At week 52, 4 out of 10 patients (40%) who received vedolizumab SC had clinical remission versus 2 out of 10 patients (20%) who received placebo (difference: 20% [95% confidence interval, –27.9 to 61.8]). Two patients (2/10, 20%) who received vedolizumab SC experienced an injection-site reaction versus none who received placebo.
Conclusions
Our results indicate that the efficacy of vedolizumab SC in a subgroup of Japanese patients with UC are similar with those in the overall VISIBLE 1 study population, and with those established with vedolizumab IV. The safety and tolerability of vedolizumab SC were generally similar to that established for vedolizumab IV. (ClinicalTrials.gov ID NCT02611830; EudraCT 2015-000480-14)

Citations

Citations to this article as recorded by  
  • Valoración de la transición de vedolizumab intravenoso a subcutáneo en pacientes con enfermedad inflamatoria intestinal
    Carmen Amor Costa, Cristina Suárez Ferrer, Laura García Ramírez, Eduardo Martín-Arranz, Joaquín Poza Cordón, José Luis Rueda García, María Sánchez Azofra, Irene González Diaz, Clara Amiama Roig, María Dolores Martín-Arranz
    Gastroenterología y Hepatología.2024; : 502201.     CrossRef
  • Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis
    Qiong Hu, Xing-zhou Tang, Fang Liu, De-wu Liu, Bo Cao
    Therapeutic Advances in Gastroenterology.2023;[Epub]     CrossRef
  • Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis
    Xinqiao Chu, Yaning Biao, Chengjiang Liu, Yixin Zhang, Chenxu Liu, Ji-zheng Ma, Yufeng Guo, Yaru Gu
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis
    Mohamed Attauabi, Gorm Roager Madsen, Flemming Bendtsen, Jakob Benedict Seidelin, Johan Burisch
    Digestive and Liver Disease.2022; 54(9): 1168.     CrossRef
  • AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
    Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori, Koichi Nakajima, Tetsuya Ishida, Yoh Ishiguro, Kazunari Kanke, Kiyonori Kobayashi, Fumihito Hirai, Kenji Watanabe, Hidehiro Mizusawa, Shuji Kishida, Yoshiharu Miura, Akira Ohta, Toshifumi Kajioka, To
    The Lancet Gastroenterology & Hepatology.2022; 7(7): 648.     CrossRef
  • Microbial changes in stool, saliva, serum, and urine before and after anti-TNF-α therapy in patients with inflammatory bowel diseases
    Yong Eun Park, Hye Su Moon, Dongeun Yong, Hochan Seo, Jinho Yang, Tae-Seop Shin, Yoon-Keun Kim, Jin Ran Kim, Yoo Na Lee, Young-Ho Kim, Joo Sung Kim, Jae Hee Cheon
    Scientific Reports.2022;[Epub]     CrossRef
  • Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
    Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
    Gut and Liver.2022; 16(5): 764.     CrossRef
  • Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
    Clotilde Remy, Bénédicte Caron, Celia Gouynou, Vincent Haghnejad, Elodie Jeanbert, Patrick Netter, Silvio Danese, Laurent Peyrin-Biroulet
    Journal of Clinical Medicine.2022; 11(24): 7296.     CrossRef
  • Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy
    Maximilian Wiendl, Emily Becker, Tanja M. Müller, Caroline J. Voskens, Markus F. Neurath, Sebastian Zundler
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Subcutaneous vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a profile of its use
    Sheridan M. Hoy
    Drugs & Therapy Perspectives.2021; 37(12): 563.     CrossRef
  • AJM300 (Carotegrast Methyl), an Oral Antagonist of α4-Integrin, as Induction Therapy for Patients with Moderately Active Ulcerative Colitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Study
    Katsuyoshi Matsuoka, Mamoru Watanabe, Toshihide Ohmori, Kouichi Nakajima, Tetsuya Ishida, Yoh Ishiguro, Kazunari Kanke, Kiyonori Kobayashi, Fumihito Hirai, Kenji Watanabe, Hidehiro Mizusawa, Shuji Kishida, Yoshiharu Miura, Akira Ohta, Toshifumi Kajioka, T
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • 7,231 View
  • 468 Download
  • 10 Web of Science
  • 11 Crossref
Close layer
Inflammatory Bowel Diseases
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Evangelia Legaki, Maria Gazouli, Ioannis E. Koutroubakis
Intest Res 2021;19(4):461-467.   Published online August 18, 2020
DOI: https://doi.org/10.5217/ir.2020.00042
AbstractAbstract PDFPubReaderePub
Background/Aims
The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs) and IFX-TLs has not been sufficiently studied thus far. To investigate the possible association of IFX-TLs with AEs in Greek patients with IBD receiving maintenance treatment with IFX.
Methods
A retrospective analysis of the registry data of the Gastroenterology Department of the University Hospital of Heraklion, from IBD patients with at least one available IFX-TL measurement during the years 2016 to 2017 was conducted. AEs reported 4 months before and 4 months after the measured IFX-TLs were recorded. The IFX-TLs of patients with or without AEs were compared.
Results
Of a total of 83 IBD patients (61 Crohn’s disease [73%]; 52 men [63%]; mean age ± standard deviation, 43.3 ± 16.0 years), 147 measurements of IFX-TLs were available (median 4.69 μg/ mL [1.32–9.16]), and 99 AEs (67.3%, 14 severe) were registered. The median IFX-TL of patients with AEs was 5.79 μg/mL (1.36– 10.25), higher than the median IFX-TL of patients without AEs (3.40 μg/mL [1.30–5.92]), but the difference was not significant (P= 0.97). The presence of infections or dermatologic reactions was not correlated with IFX-TLs. There was no difference in the prevalence of the total AEs (66.7% vs. 73.3%, P= 0.77) or in the analysis of AEs by group between patients with IFX-TLs ≥ 15 μg/ mL and patients with IFX-TLs < 15 μg/mL.
Conclusions
IFX-TLs are not significantly associated with the development of AEs in IBD patients receiving maintenance treatment with IFX.

Citations

Citations to this article as recorded by  
  • Identifying risk factors of anti‐TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease
    Karen van Hoeve, Debby Thomas, Tom Hillary, Ilse Hoffman, Erwin Dreesen
    Journal of Pediatric Gastroenterology and Nutrition.2024; 78(1): 95.     CrossRef
  • Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD)
    Daniela Kosorínová, Pavlína Suchá, Zuzana Havlíčeková, Marek Pršo, Pavol Dvoran, Peter Bánovčin
    Česko-slovenská pediatrie.2024; 79(4): 213.     CrossRef
  • Comparison of the Pharmacokinetics of CT-P13 Between Crohn’s Disease and Ulcerative Colitis
    Eun Soo Kim, Sung Kook Kim, Dong Il Park, Hyo Jong Kim, Yoo Jin Lee, Ja Seol Koo, Eun Sun Kim, Hyuk Yoon, Ji Hyun Lee, Ji Won Kim, Sung Jae Shin, Hyung Wook Kim, Hyun-Soo Kim, Young Sook Park, You Sun Kim, Tae Oh Kim, Jun Lee, Chang Hwan Choi, Dong Soo Ha
    Journal of Clinical Gastroenterology.2023; 57(6): 601.     CrossRef
  • Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease
    Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, Nikolaos-Panagiotis Andreou, Maria Gazouli, Ioannis E. Koutroubakis
    International Journal of Colorectal Disease.2022; 37(3): 639.     CrossRef
  • Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
    Jihye Park, Jae Hee Cheon
    Gut and Liver.2021; 15(5): 641.     CrossRef
  • Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
    Ji Young Chang, Jae Hee Cheon
    Precision and Future Medicine.2021; 5(4): 151.     CrossRef
  • 5,359 View
  • 179 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Case Reports
Miscellaneous
Hydroxyurea associated ileocecal valve ulcer: evidence for causality
Thevaraajan Jayaraman, Ruveena Bhavani Rajaram, Gin Gin Gan, Ida Hilmi
Intest Res 2021;19(4):468-471.   Published online December 1, 2020
DOI: https://doi.org/10.5217/ir.2020.00099
AbstractAbstract PDFPubReaderePub
Hydroxyurea is an antimetabolite drug that is commonly used in many hematological disorders. Ulcer formation in the gastrointestinal tract is a rare phenomenon associated with this drug. We report a case of a 73-year-old woman who was found to have an isolated ileocecal valve ulcer while on hydroxyurea 1 g daily for essential thrombocythemia. A comprehensive evaluation ruled out all other causes. The cytoreductive therapy was switched to anagrelide and the endoscopic evaluation 6 months later showed complete healing of the ulcer. However, the hydroxyurea was resumed due to increasing platelet counts and intolerance to dose increments of the anagrelide. Subsequently, the patient was found to have a recurrence of the ulcer. Apart from oral ulcers, there have also been reports of ulcers involving the small bowel and the colon associated with the use of hydroxyurea. The pathophysiology of the non-oral gastrointestinal ulceration in relation to this drug is unclear. Withdrawal of the drug typically leads to complete resolution. Increasing awareness of the rare association between the use of hydroxyurea and nonoral gastrointestinal ulcers is essential for early detection to prevent related complications.

Citations

Citations to this article as recorded by  
  • Repairing of recurrent leg ulcer induced by hydroxyurea with posterior tibial artery perforator propeller flap: Case report
    Zheng-Dong Wan, Wu-Zhou Li
    International Journal of Surgery Case Reports.2024; 114: 109049.     CrossRef
  • Esophageal and Ileal Ulcers Caused by Hydroxycarbamide: A Case Report and Literature Review
    Takumi Inaba, Yu Yamamoto, Kaho Hirayama, Takuma Kobayashi, Naoto Izumi, Hirotsugu Sakamoto, Shuji Hatakeyama, Masami Matsumura
    Internal Medicine.2024;[Epub]     CrossRef
  • 6,184 View
  • 181 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
IBD
Pediatric Crohn’s disease with severe morbidity manifested by gastric outlet obstruction: two cases report and review of the literature
Eun Sil Kim, Ji Hyung Park, Yon Ho Choe, Mi Jin Kim
Intest Res 2021;19(4):472-477.   Published online October 29, 2020
DOI: https://doi.org/10.5217/ir.2020.00072
AbstractAbstract PDFPubReaderePub
Crohn’s disease (CD) presenting as gastric outlet obstruction is rare but serious clinical presentation of CD causing severe morbidity. However, there have been few case reports concerning this disorder in East Asian children and adolescents. The current case report describes 2 pediatric patients with CD who had had gastric outlet obstruction as an initial symptom of CD. Two pediatric patients developed postprandial vomiting, bloating, and unintentional weight loss. The upper endoscopy result indicated that there was pyloric obstruction with mucosal edema, inflammation and ulcers. The serologic test and colonoscopy results suggested CD. These patients were treated with infliximab, and endoscopic balloon dilation without surgery and showed remarkable improvement in obstructing symptoms with maintaining clinical and biochemical remission. This case report elucidates the benefits of early intervention using infliximab and endoscopic balloon dilation to improve gastric outlet obstruction and achieve baseline recovery in patients with upper gastrointestinal B2 phenotype of CD.

Citations

Citations to this article as recorded by  
  • Upper gastrointestinal tract involvement of Crohn disease: clinical implications in children and adolescents
    Eun Sil Kim, Mi Jin Kim
    Clinical and Experimental Pediatrics.2022; 65(1): 21.     CrossRef
  • 5,444 View
  • 157 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Brief Communcation
IBD
Anti-inflammatory properties of Escherichia coli Nissle 1917 in a murine colitis model
Jihye Park, Da Hye Kim, Soochan Kim, Hyun Woo Ma, I Seul Park, Mijeong Son, Ji Hyung Kim, Yoojin Shin, Seung Won Kim, Jae Hee Cheon
Intest Res 2021;19(4):478-481.   Published online October 26, 2021
DOI: https://doi.org/10.5217/ir.2021.00121
PDFPubReaderePub

Citations

Citations to this article as recorded by  
  • Expectations for employing Escherichia coli Nissle 1917 in food science and nutrition
    Miaomiao Hu, Tao Zhang, Ming Miao, Kewen Li, Qingmin Luan, Guilian Sun
    Critical Reviews in Food Science and Nutrition.2024; : 1.     CrossRef
  • Potential of using an engineered indole lactic acid producing Escherichia coli Nissle 1917 in a murine model of colitis
    Chrysoula Dimopoulou, Priscila Regina Guerra, Martin Steen Mortensen, Katja Ann Kristensen, Mikael Pedersen, Martin Iain Bahl, Morten Alexander Otto Sommer, Tine Rask Licht, Martin Frederik Laursen
    Scientific Reports.2024;[Epub]     CrossRef
  • Priority order of neonatal colonization by a probiotic or pathogenic Escherichia coli strain dictates the host response to experimental colitis
    Tomas Hudcovic, Petra Petr Hermanova, Hana Kozakova, Oldrich Benada, Olga Kofronova, Martin Schwarzer, Dagmar Srutkova
    Frontiers in Microbiology.2024;[Epub]     CrossRef
  • Anti-inflammatory properties of butyrate-producing atypical Escherichia coli in a murine colitis model
    Ji Hyung Kim, Jee In Yoo, Hyun Woo Ma, I Seul Park, Mijeong Son, Yoojin Shin, Ki Beom Kim, Seung Won Kim, Si Jae Park, Jihye Park
    Intestinal Research.2023; 21(2): 266.     CrossRef
  • Microbial Modulation in Inflammatory Bowel Diseases
    Jongwook Yu, Jae Hee Cheon
    Immune Network.2022;[Epub]     CrossRef
  • 5,115 View
  • 121 Download
  • 5 Web of Science
  • 5 Crossref
Close layer
Images of the Issue
Miscellaneous
An elderly woman with severe enteritis mimicking infectious enteritis
Kazunori Nagashima, Takashi Kato, Taichi Kimura, Kazuma Kishi, Urara Baba
Intest Res 2021;19(4):482-484.   Published online July 3, 2020
DOI: https://doi.org/10.5217/ir.2020.00038
PDFPubReaderePub
  • 5,245 View
  • 187 Download
Close layer

Intest Res : Intestinal Research
Close layer
TOP